Psoriasis is a chronic inflammatory disorder with an overall prevalence of approximately 3% among US individuals 20 years of age and older, making it one of the most common immune-mediated diseases in the US [ 1 , 2 ]. The overall economic burden …

The NPF’s treatment targets for plaque psoriasis provide a comprehensive treat-to-target (T2T) strategy to guide therapeutic approaches for clinical practice in the USA, with the goal of reducing disease burden and improving patient outcomes [ 1 ].

Nail psoriasis (NP) is a chronic, difficult-to-treat condition affecting around half of patients with psoriasis. It is associated with considerable social stigma and impairment of patients’ quality of life [ 1 ]. The presence of nail changes not …

Psoriasis is a chronic, relapsing, immune-mediated skin disease. In Europe, the prevalence of psoriasis ranges from 0.73% in Scotland to 2.9% in Italy [ 1 ], which is roughly equal to 1,500,000 Italians [ 2 ].

Approximately 6 million people in China have psoriasis [ 1 ], an incurable, immune-mediated, chronic, recurrent inflammatory disease [ 2 ], the majority of whom have moderate-to-severe plaque psoriasis [ 3 ]. The estimated age-standardized …

Psoriasis is a chronic, incurable inflammatory skin disease characterized by red, scaly plaques that can develop across different body areas as a result of complex gene-environmental-mediated epidermal hyperproliferation [ 1 , 2 ]. In China, more …

Plaque psoriasis (hereinafter psoriasis) is a chronic relapsing inflammatory skin disease characterized by red, scaly plaques and pruritus, which often requires long-term therapy. Topical therapies are commonly used to treat psoriasis given their …

Psoriasis is a chronic inflammatory skin disease that can significantly affect patients’ quality of life [ 1 , 2 ]. In recent years, as the pathogenesis of the disease has become better understood, a variety of novel targeted treatments have become …

Plaque psoriasis is an immune-mediated inflammatory condition affecting skin, joints, and several other systems [ 1 ]. As a result of its chronic relapsing–remitting course, psoriasis has a considerable effect on quality of life [ 1 , 2 ].

For patients with chronic diseases such as axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and plaque psoriasis (PsO), treatment goals usually include attaining remission preferably within the first 12 weeks of treatment [ 1 – 3 ]. In …

This article is published with digital features, including a graphical abstract to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.24893724 .

An interactive infographic provided for this article: https://vahub.lilly.com/gooderham_dermatologyandtherapy_2024 .

Psoriasis is a chronic, inflammatory skin disease that affects approximately 2% of people worldwide [ 1 ]. Pruritus affects 60–90% of patients with psoriasis and substantially impacts health-related quality of life [ 2 – 5 ]. Itching can negatively …

Psoriasis is a chronic, immune-mediated inflammatory skin disease, characterized by proliferation of keratinocytes and accumulation of immune cells in the affected skin, with an estimated prevalence of 2% in the European adult population [ 1 ].

Plaque psoriasis is the most common form of psoriasis [ 1 ] and the concept of this highly prevalent disease [ 2 , 3 ] involving accumulating disease memory and increasing impact of chronification is now well established [ 4 ]. However, further …

Psoriasis is one of the most common chronic inflammatory skin diseases, and plaque psoriasis is by far the most common clinical form of psoriasis [ 1 , 2 ]. Management of psoriasis is challenging, particularly in pediatric and elderly patients …

Plaque psoriasis is a chronic, immune-mediated inflammatory disease, with an estimated prevalence of ≥ 1.5% in regions such as Australasia and Western and Central Europe, and in areas of North America [ 1 ]. Ustekinumab is a monoclonal antibody …